Outcomes of Anti-BCMA CAR T Cell Therapy for Relapsed/refractory Multiple Myeloma: A Meta-Analysis

被引：0
|
作者：
Gagelmann, Nico [1 ]
Ayuk, Francis [1 ]
Atanackovic, Djordje [2 ]
Kroeger, Nicolaus [1 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Utah, Salt Lake City, UT USA
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O122
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
    Zhang, Xiaohui
    Ouyang, Chenxi
    Sun, Guofeng
    Liu, Hongfeng
    Qi, Junyuan
    Suo, Xiaohui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
  • [2] Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
    Zhang, Lina
    Shen, Xuxing
    Yu, Wenjun
    Li, Jing
    Zhang, Jue
    Zhang, Run
    Li, Jianyong
    Chen, Lijuan
    ANNALS OF MEDICINE, 2021, 53 (01) : 1547 - 1559
  • [3] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
    Raje, Noopur
    Berdeja, Jesus
    Lin, Yi
    Siegel, David
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Turka, Ashley
    Lam, Lyh-Ping
    Morgan, Richard A.
    Friedman, Kevin
    Massaro, Monica
    Wang, Julie
    Russotti, Greg
    Yang, Zhihong
    Campbell, Timothy
    Hege, Kristen
    Petrocca, Fabio
    Quigley, M. Travis
    Munshi, Nikhil
    Kochenderfer, James N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (18): : 1726 - 1737
  • [4] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [5] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
    Yao, Xin
    Zhu, Shigui
    Huang, Jiaqi
    Qu, Xiaoyan
    Zhu, Judy
    Wei, Yutian
    Lan, Liping
    Lv, Xiaoteng
    Wu, Junfeng
    Wang, Rirfei
    Yang, Dingzhu
    Zheng, Chengxiao
    Zhao, DiJun
    Fan, Lei
    Huang, Fei
    Lu, Hua
    Zhang, Chaocan
    Chen, Cheng
    Li, Yanfeng
    Ren, Jiaqiang
    Zhang, Li
    Humphries, Michael
    Li, Jianyong
    Yao, Yihong
    BLOOD, 2019, 134
  • [6] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
    Arora, Sankalp
    Giri, Smith
    Godby, Kelly Nicole
    Ravi, Gayathri
    Costa, Luciano J.
    Bal, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
    Liang, Zhiyu
    Li, Ping
    Kang, Liqing
    Zhou, Lili
    Xu, Yang
    Ye, Shiguang
    Du, Juan
    Li, Bing
    Wang, Yiwen
    Yu, Lei
    Qian, Wenbin
    Liang, Aibin
    BLOOD ADVANCES, 2022, 6 (01) : 293 - 296
  • [8] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    He, Shao-long
    Cheng, Yu-hang
    Wang, Di
    Xu, Meng-lei
    Que, Yi-mei
    Xu, Yan-jie
    Ma, Liang-ming
    Li, Chun-rui
    Zhou, Jian-feng
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 474 - 481
  • [9] Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
    Quintas-Cardama, Alfonso
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03):
  • [10] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
12345